WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Case 7 - ACh Cmap, Cholinergic Antagonist Determined History, genetics, high risk population Epidemiology and risk factors, Cholinergic Antagonist Determined Physiologic changes Organ function changes, Pharmacologic Intervention Alternatives Considerations for selection Physostigmine, Organ function changes others possible Dry eyes, constipation, dry mouth, dizziness, No Non-Rx Meds, Herbals, or Viatmins Taken Screen for Drug side effects, Treatment strategies ???? Pharmacologic Intervention Alternatives, Transdermal scopolamine Screen for Drug side effects, Physostigmine Weigh risks Adverse Drug Effects and Contraindications, Patient Presentation in Chart and Clinically No known allergies, Medication History Review No Non-Rx Meds, Herbals, or Viatmins Taken, Half-life of scopolamine is 9.5 hours ???? Blurred vision should resolve in 24 hours or less, Clinical Presentation ???? Physical findings, Treatment strategies ???? Nonpharmacologic Interventions, Physical findings Check vitals Dilated pupil in left eye, increased blood pressure, increased heart rate, increased body temperature, Cholinergic Antagonist Determined Physiologic changes Receptor changes, Organ function changes seen Mydriasis & cycloplegia, Muscarinic Acetylcholine Receptor ???? M3 block, Physostigmine Actions Increase acetylcholine, Clinical Presentation Take history Healthy & Active Lifestyle, Patient Presentation in Chart and Clinically ???? Clinical Presentation